A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans.
Authors: Legon W, Adams S, Bansal P, Patel PD, Hobbs L, Ai L, Mueller JK, Meekins G, Gillick BT
Low intensity transcranial focused ultrasound (LIFU) is a promising method of non-invasive neuromodulation that uses mechanical energy to affect neuronal excitability. LIFU confers high spatial resolution and adjustable focal lengths for precise neuromodulation of discrete regions in the human brain. Before the full potential of low intensity ultrasound for research and clinical application can be investigated, data on the safety of this technique is indicated. Here, we provide an evaluation of the safety of LIFU for human neuromodulation through participant report and neurological assessment with a comparison of symptomology to other forms of non-invasive brain stimulation. Participants (N = 120) that were enrolled in one of seven human ultrasound neuromodulation studies in one laboratory at the University of Minnesota (2015-2017) were queried to complete a follow-up Participant Report of Symptoms questionnaire assessing their self-reported experience and tolerance to participation in LIFU research (I<sub>sppa</sub> 11.56-17.12 W/cm<sup>2</sup>) and the perceived relation of symptoms to LIFU. A total of 64/120 participant (53%) responded to follow-up requests to complete the Participant Report of Symptoms questionnaire. None of the participants experienced serious adverse effects. From the post-hoc assessment of safety using the questionnaire, 7/64 reported mild to moderate symptoms, that were perceived as 'possibly' or 'probably' related to participation in LIFU experiments. These reports included neck pain, problems with attention, muscle twitches and anxiety. The most common unrelated symptoms included sleepiness and neck pain. There were initial transient reports of mild neck pain, scalp tingling and headache that were extinguished upon follow-up. No new symptoms were reported upon follow up out to 1 month. The profile and incidence of symptoms looks to be similar to other forms of non-invasive brain stimulation.
Introduction
Purpose
Transcranial ultrasound stimulation
Study Objective
To assess the safety and participant-reported symptoms of low intensity transcranial focused ultrasound (LIFU) used for human neuromodulation.
Animal model / Human subject
Human (Homo sapiens), strain: N/A, age: 22.96+-2.14 years, sex: 29 male and 35 female
Disease model
Healthy
MRI or image guidance method
MRI-based neuronavigation
Targeted brain region(s)
Thalamus
Outcomes and Safety
Summary of Outcomes
LIFU is safe with no serious adverse effects. Small subset of people report mild to moderate symptoms. Initial transient symtoms resolved by 1 month follow-up.
Duration of biological effect
1 month
Safety-related matter
No serious adverse effects were observed; 7/64 participants reported mild-to-moderate symptoms (e.g., neck pain, attention problems, muscle twitches, anxiety) that were possibly or probably related to LIFU, these were transient (resolved by one month), and no seizures or other serious events were reported.
Brain Region
Ultrasound Parameters
Ultrasound instrument
Single-element focused ultrasound transducer
FUS Frequency
0.5 MHz
FUS Intensity
11.56-17.12 W/cm2
FUS Mode
pulsed
Pulse duration
360 us
Duration of a single FUS session
0.5 s
Focal Characteristics
Focal depth: None; Focal length: 71, 24, 25 mm; Aperture size: 63, 30 mm
Treatment frequency
Single session
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search